Kyverna Therapeutics, Inc. (KYTX) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Kyverna Therapeutics reported revenue of $0. Net income was -$161.3M, or -$3.64 per diluted share. Operating activities generated -$153.7M of cash, leaving -$153.7M of free cash flow. At fiscal year end, Kyverna Therapeutics held $293.8M in total assets against $61.5M in total liabilities, including $124.1M of cash and equivalents.
Open the full interactive Kyverna Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Kyverna Therapeutics Key Stats
| Share Price | $5.77 |
|---|---|
| Market Cap | $351.4M |
| 52-Week Range | $5.77 – $11.25 |
| Shares Outstanding | 60.9 million (basic, 2026 Q2) |
Kyverna Therapeutics Income Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Revenue | $0 | $0 |
| Operating Income | -$142.6M | -$169.8M |
| Pre-Tax Income | -$127.5M | -$161.3M |
| Income Tax | $0 | $0 |
| Net Income | -$127.5M | -$161.3M |
| Diluted EPS | -$3.33 | -$3.64 |
Kyverna Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$36.8M | -$37.8M | -$39.7M | -$38.3M |
| Diluted EPS | -$0.85 | -$0.85 | -$0.66 | -$0.63 |
Kyverna Therapeutics Balance Sheet
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash & Equivalents | $96.6M | $124.1M |
| Current Assets | $290.6M | $283.0M |
| Total Assets | $304.6M | $293.8M |
| Current Liabilities | $33.8M | $36.5M |
| Total Long-Term Debt | — | $24.7M |
| Total Liabilities | $38.1M | $61.5M |
| Shareholders' Equity | $266.6M | $232.3M |
Kyverna Therapeutics Cash Flow Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash From Operations | -$114.2M | -$153.7M |
| Cash From Investing | -$160.9M | $40.0M |
| Cash From Financing | $337.1M | $141.2M |
| Free Cash Flow | -$116.5M | -$153.7M |
Figures from Kyverna Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Kyverna Therapeutics financials page for every line item.
Kyverna Therapeutics Company Profile
| Ticker | KYTX |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Emeryville, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001994702 |
Frequently Asked Questions
What was Kyverna Therapeutics' revenue in fiscal 2025?
Kyverna Therapeutics (KYTX) reported revenue of $0 for fiscal 2025.
What was Kyverna Therapeutics' net income in fiscal 2025?
Kyverna Therapeutics reported net income of -$161.3M for fiscal 2025.
What was Kyverna Therapeutics' earnings per share (EPS) in fiscal 2025?
Kyverna Therapeutics' diluted EPS was -$3.64 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Kyverna Therapeutics generate in fiscal 2025?
Kyverna Therapeutics generated -$153.7M of free cash flow in fiscal 2025.
What was Kyverna Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Kyverna Therapeutics reported revenue of $0.
How much debt does Kyverna Therapeutics have?
Kyverna Therapeutics reported $24.7M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Kyverna Therapeutics are outstanding?
Kyverna Therapeutics reported a weighted average of 60.9 million basic shares outstanding in 2026 Q2.
What is Kyverna Therapeutics' market cap?
Based on its latest closing price, Kyverna Therapeutics (KYTX) has a market capitalization of about $351.4M.
When does Kyverna Therapeutics' fiscal year end?
Kyverna Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Kyverna Therapeutics headquartered?
Kyverna Therapeutics lists its business address in Emeryville, California in its SEC filings.
Kyverna Therapeutics Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →